类器官在肿瘤研究中的应用

doi:10.12280/gjfckx.20211126

摘要/Abstract

摘要：

近年来,肿瘤精准治疗及愈来愈深入的肿瘤机制研究对肿瘤研究模型提出了更高的要求。肿瘤类器官,一种来源于干细胞的体外3D肿瘤模型,因其对肿瘤体内形态结构及生物学特性的模拟,引起了广泛的关注。多项研究表明,与肿瘤细胞系、原代细胞等常用的肿瘤模型相比,肿瘤类器官直接来源于患者,更能体现患者特有的肿瘤体细胞突变和生物学特性。由于类器官能在短时间内实现体外大规模扩增,对肿瘤类器官进行高通量药物筛选可作为患者精准治疗的参考。此外,类器官能模拟体内肿瘤微环境,保留细胞与细胞、细胞与细胞外基质的相互影响;同时类器官在体外可被基因编辑。类器官的这些特性使其成为适于在肿瘤精准治疗及基础研究中推广应用的体外肿瘤模型。

关键词: 类器官, 肿瘤, 药物筛选试验,抗肿瘤, 精准治疗, 基因编辑

Abstract:

Nowadays, precise treatment and much more advanced tumor mechanism research have higher demand for tumor models. Tumor organoids, stem cell originated three-dimensional in vitro tumor models. Due to its simulation of in vivo tumor structure and characteristic, tumor organoids attract extensive attention. Compared with previous tumor models such as tumor cell lines and primary cells, a number of studies have shown that the tumor organoids are directly derived from patients, which can retain the somatic mutations and biological characteristics. Thanks to its short time expansion in vitro, tumor organoids in high-throughput drug screening can be used as a reference for patients′ precise treatment. Besides, tumor organoids can mimic the internal tumor microenvironment, retain the interaction between cells and extracellular matrix. At the same time, tumor organoids are available for gene editing. These characteristics of organoids make them suitable for promoting application as an in vitro tumor model in tumor precision therapy and basic research.

Key words: Organoids, Neoplasms, Drug screening assays,antitumor, Precision treatment, Gene editing

黄华, 姚书忠. 类器官在肿瘤研究中的应用[J]. 国际妇产科学杂志, 2022, 49(2): 176-180.

HUANG Hua, YAO Shu-zhong. Application of Organoid in Cancer Research[J]. Journal of International Obstetrics and Gynecology, 2022, 49(2): 176-180.

参考文献 37

[1]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5):646-674. doi: 10.1016/j.cell.2011.02.013. doi: 10.1016/j.cell.2011.02.013
[2]	Stadler M, Walter S, Walzl A, et al. Increased complexity in carcinomas: Analyzing and modeling the interaction of human cancer cells with their microenvironment[J]. Semin Cancer Biol, 2015, 35:107-124. doi: 10.1016/j.semcancer.2015.08.007. doi: 10.1016/j.semcancer.2015.08.007 pmid: 26320002
[3]	Li M, Izpisua Belmonte JC. Organoids-Preclinical Models of Human Disease[J]. N Engl J Med, 2019, 380(6):569-579. doi: 10.1056/NEJMra1806175. doi: 10.1056/NEJMra1806175
[4]	Clevers H. Modeling Development and Disease with Organoids[J]. Cell, 2016, 165(7):1586-1597. doi: 10.1016/j.cell.2016.05.082. doi: S0092-8674(16)30729-2 pmid: 27315476
[5]	Nath S, Devi GR. Three-dimensional culture systems in cancer research: Focus on tumor spheroid model[J]. Pharmacol Ther, 2016, 163:94-108. doi: 10.1016/j.pharmthera.2016.03.013. doi: 10.1016/j.pharmthera.2016.03.013
[6]	Tuveson D, Clevers H. Cancer modeling meets human organoid technology[J]. Science, 2019, 364(6444):952-955. doi: 10.1126/science.aaw6985. doi: 10.1126/science.aaw6985 pmid: 31171691
[7]	Laurent J, Frongia C, Cazales M, et al. Multicellular tumor spheroid models to explore cell cycle checkpoints in 3D[J]. BMC Cancer, 2013, 13:73. doi: 10.1186/1471-2407-13-73. doi: 10.1186/1471-2407-13-73
[8]	Drost J, Clevers H. Organoids in cancer research[J]. Nat Rev Cancer, 2018, 18(7):407-418. doi: 10.1038/s41568-018-0007-6. doi: 10.1038/s41568-018-0007-6
[9]	Papapetrou EP. Patient-derived induced pluripotent stem cells in cancer research and precision oncology[J]. Nat Med, 2016, 22(12):1392-1401. doi: 10.1038/nm.4238. doi: 10.1038/nm.4238 pmid: 27923030
[10]	Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening[J]. Nat Med, 2017, 23(12):1424-1435. doi: 10.1038/nm.4438. doi: 10.1038/nm.4438 pmid: 29131160
[11]	van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients[J]. Cell, 2015, 161(4):933-945. doi: 10.1016/j.cell.2015.03.053. doi: 10.1016/j.cell.2015.03.053 pmid: 25957691
[12]	Maru Y, Tanaka N, Ebisawa K, et al. Establishment and characterization of patient-derived organoids from a young patient with cervical clear cell carcinoma[J]. Cancer Sci, 2019, 110(9):2992-3005. doi: 10.1111/cas.14119. doi: 10.1111/cas.14119
[13]	Yan HHN, Siu HC, Law S, et al. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening[J]. Cell Stem Cell, 2018, 23(6):882-897.e11. doi: 10.1016/j.stem.2018.09.016. doi: 10.1016/j.stem.2018.09.016
[14]	Mazzucchelli S, Piccotti F, Allevi R, et al. Establishment and Morphological Characterization of Patient-Derived Organoids from Breast Cancer[J]. Biol Proced Online, 2019, 21:12. doi: 10.1186/s12575-019-0099-8. doi: 10.1186/s12575-019-0099-8 pmid: 31223292
[15]	Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer[J]. Cell, 2015, 160(1/2):324-338. doi: 10.1016/j.cell.2014.12.021. doi: 10.1016/j.cell.2014.12.021
[16]	Weber C. A biobank for bladder cancer[J]. Nat Cell Biol, 2018, 20(6):634. doi: 10.1038/s41556-018-0114-3. doi: 10.1038/s41556-018-0114-3
[17]	Kopper O, de Witte CJ, Lõhmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity[J]. Nat Med, 2019, 25(5):838-849. doi: 10.1038/s41591-019-0422-6. doi: 10.1038/s41591-019-0422-6 pmid: 31011202
[18]	Lin M, Gao M, Cavnar MJ, et al. Utilizing gastric cancer organoids to assess tumor biology and personalize medicine[J]. World J Gastrointest Oncol, 2019, 11(7):509-517. doi: 10.4251/wjgo.v11.i7.509. doi: 10.4251/wjgo.v11.i7.509
[19]	Choi SI, Jeon AR, Kim MK, et al. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples[J]. Front Oncol, 2019, 9:875. doi: 10.3389/fonc.2019.00875. doi: 10.3389/fonc.2019.00875 pmid: 31572675
[20]	Sachs N, de Ligt J, Kopper O, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity[J]. Cell, 2018, 172(1/2):373-386.e10. doi: 10.1016/j.cell.2017.11.010. doi: 10.1016/j.cell.2017.11.010
[21]	Driehuis E, van Hoeck A, Moore K, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening[J]. Proc Natl Acad Sci U S A, 2019, 116(52):26580-26590. doi: 10.1073/pnas.1911273116. doi: 10.1073/pnas.1911273116
[22]	Byrne AT, Alférez DG, Amant F, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts[J]. Nat Rev Cancer, 2017, 17(4):254-268. doi: 10.1038/nrc.2016.140. doi: 10.1038/nrc.2016.140
[23]	Jung J, Seol HS, Chang S. The Generation and Application of Patient-Derived Xenograft Model for Cancer Research[J]. Cancer Res Treat, 2018, 50(1):1-10. doi: 10.4143/crt.2017.307. doi: 10.4143/crt.2017.307
[24]	Ganesh K, Wu C, O′Rourke KP, et al. A rectal cancer organoid platform to study individual responses to chemoradiation[J]. Nat Med, 2019, 25(10):1607-1614. doi: 10.1038/s41591-019-0584-2. doi: 10.1038/s41591-019-0584-2
[25]	Yao Y, Xu X, Yang L, et al. Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer[J]. Cell Stem Cell, 2020, 26(1):17-26.e6. doi: 10.1016/j.stem.2019.10.010. doi: S1934-5909(19)30431-X pmid: 31761724
[26]	Weeber F, Ooft SN, Dijkstra KK, et al. Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery[J]. Cell Chem Biol, 2017, 24(9):1092-1100. doi: 10.1016/j.chembiol.2017.06.012. doi: S2451-9456(17)30226-X pmid: 28757181
[27]	Guo WM, Loh XJ, Tan EY, et al. Development of a magnetic 3D spheroid platform with potential application for high-throughput drug screening[J]. Mol Pharm, 2014, 11(7):2182-2189. doi: 10.1021/mp5000604. doi: 10.1021/mp5000604
[28]	Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response[J]. Nat Med, 2015, 21(11):1318-1325. doi: 10.1038/nm.3954. doi: 10.1038/nm.3954
[29]	DiMasi JA, Reichert JM, Feldman L, et al. Clinical approval success rates for investigational cancer drugs[J]. Clin Pharmacol Ther, 2013, 94(3):329-335. doi: 10.1038/clpt.2013.117. doi: 10.1038/clpt.2013.117 pmid: 23739536
[30]	Dhimolea E, de Matos Simoes R, Kansara D, et al. An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence[J]. Cancer Cell, 2021, 39(2):240-256.e11. doi: 10.1016/j.ccell.2020.12.002. doi: 10.1016/j.ccell.2020.12.002 pmid: 33417832
[31]	Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers[J]. Science, 2018, 359(6378):920-926. doi: 10.1126/science.aao2774. doi: 10.1126/science.aao2774 pmid: 29472484
[32]	Jabs J, Zickgraf FM, Park J, et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations[J]. Mol Syst Biol, 2017, 13(11):955. doi: 10.15252/msb.20177697. doi: 10.15252/msb.20177697
[33]	Skardal A, Shupe T, Atala A. Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling[J]. Drug Discov Today, 2016, 21(9):1399-1411. doi: 10.1016/j.drudis.2016.07.003. doi: 10.1016/j.drudis.2016.07.003
[34]	Drost J, van Jaarsveld RH, Ponsioen B, et al. Sequential cancer mutations in cultured human intestinal stem cells[J]. Nature, 2015, 521(7550):43-47. doi: 10.1038/nature14415. doi: 10.1038/nature14415
[35]	Matano M, Date S, Shimokawa M, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids[J]. Nat Med, 2015, 21(3):256-262. doi: 10.1038/nm.3802. doi: 10.1038/nm.3802 pmid: 25706875
[36]	Tsai S, McOlash L, Palen K, et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models[J]. BMC Cancer, 2018, 18(1):335. doi: 10.1186/s12885-018-4238-4. doi: 10.1186/s12885-018-4238-4
[37]	Neal JT, Li X, Zhu J, et al. Organoid Modeling of the Tumor Immune Microenvironment[J]. Cell, 2018, 175(7):1972-1988.e16. doi: 10.1016/j.cell.2018.11.021. doi: 10.1016/j.cell.2018.11.021